Company Interview / A fast-paced Race in the healthcare sector

Key points:

Race Oncology (ASX:RAC) preparing phase three trial for acute myeloid leukaemia Launching a US trial for EGFR-mutant small cell lung cancer in combination with AstraZeneca’s Tagrisso$25 million in outstanding options, with funding needed to accelerate clinical progress Focus on rare indications and major international cancer markets

Race Oncology (ASX:RAC) is advancing two new clinical trials, Daniel Tillett states, targeting significant unmet needs in cancer treatment. Tillett outlines the first trial as a phase three study in acute myeloid leukaemia, an orphan indication allowing for quicker approval via a single trial with about 150 patients. Preparations for this trial’s commencement are set for next year.

Tillett highlights a second upcoming clinical trial focused on US small cell lung cancer, specifically EGFR-mutant small cell lung cancer. This trial will combine Race Oncology’s drug with AstraZeneca’s Tagrisso, the leading therapy in the space. Tillett elaborates on the complexity of this cancer, noting it is more prevalent among non-smokers and individuals of East Asian descent. Around 2.5 million cases of lung cancer are diagnosed annually, with EGFR mutations representing a significant proportion in select regions.

Tillett points to $25 million of Race Oncology options due in May 2026 as a crucial funding source for both trials. While about $4 million in options have been converted, further shareholder participation will enable the company to launch these studies sooner. The new trials are regarded as highly significant steps for Race Oncology’s growth and clinical impact.